Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's management will present a corporate update available on demand from August 15, 2024, at 7:00 a.m. ET.

Additionally, Dr. Victor Chong, Chief Medical Officer, will take part in a panel discussion on the Evolving Therapeutic Landscape of AMD. Interested parties can access the live and archived webcast presentation through the Investors section of Clearside's website under Events and Presentations.

ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced that management will present a corporate update at the H.C. Wainwright 4^th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel discussion on the Evolving Therapeutic Landscape of AMD.

A link to the live and archived webcast presentation may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When is Clearside Biomedical (CLSD) presenting at the H.C. Wainwright Ophthalmology Conference?

Clearside Biomedical (CLSD) will present a corporate update on demand starting August 15, 2024, at 7:00 a.m. ET at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.

What is Clearside Biomedical's (CLSD) area of expertise?

Clearside Biomedical (CLSD) specializes in delivering therapies to the back of the eye through the suprachoroidal space (SCS®).

Who from Clearside Biomedical (CLSD) is participating in the AMD panel discussion?

Dr. Victor Chong, Chief Medical Officer of Clearside Biomedical (CLSD), will participate in a panel discussion on the Evolving Therapeutic Landscape of AMD at the conference.

How can investors access Clearside Biomedical's (CLSD) presentation at the H.C. Wainwright conference?

Investors can access the live and archived webcast presentation through the Investors section of Clearside Biomedical's (CLSD) website under Events and Presentations.